Navigation Links
Lilly and BioMS Medical Announce Global Licensing and Development Agreement
Date:12/17/2007

Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for the

Treatment of Multiple Sclerosis

INDIANAPOLIS and EDMONTON, Alberta, Dec. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that the two companies have entered into a licensing and development agreement granting Lilly exclusive worldwide rights to BioMS Medical's lead multiple sclerosis (MS) compound, MBP8298. The compound is currently being evaluated in two pivotal phase III clinical trials in secondary progressive MS (SPMS) and one phase II clinical trial in relapsing-remitting MS (RRMS).

Under the terms of the agreement, Lilly and BioMS Medical will collaborate on the development of MBP8298 and will also share in certain development costs with Lilly being responsible for future R&D, manufacturing and marketing activities. BioMS Medical will receive an upfront payment of $87 million, as well as potential development and sales milestones up to $410 million and escalating royalties on sales commensurate with the current stage of development of the product if MBP8298 is successfully commercialized. BioMS Medical will continue to oversee the current clinical trials. Other terms of the deal were not disclosed.

"Lilly is pleased to add yet another promising late-stage compound to our portfolio," said Dr. William W. Chin, M.D., vice president of discovery research and clinical investigation for Lilly. "Multiple sclerosis is a disease with significant unmet patient needs. MBP8298 has shown potential in slowing the progression of secondary progressive MS, and thus may provide an effective therapeutic option for patients with this debilitating disease. We are also hopeful t
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical to present at BioContact 2007
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
8. BioMS Medical announces third quarter 2007 results
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
11. AEterna Zentaris completes management team with the appointment of Chief Medical Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009).... 9 NexBio, Inc. announced the pre...College of Allergy, Asthma, and Immunology in Miam... (Fludase®), a Sialidase, Decreases Airway Re...in Animal Models of Asthma". ,, DAS181 (Fludase...t-targeting drug candidate being studied in human ...
(Date:11/9/2009)...vember 9 Following the provision o...Drug Administration (FDA), privately,owned UK comp...international.com ) has been informed that its inn...n awarded an Orphan-Drug,designation for the treat..., ALS, also known as Lou Gehrig,s disease, is ...
(Date:11/6/2009)...6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc...iled the Form 52-109F1 Certification of Annual Fil...r and James Long, the Chief Financial Officer (the...in connection with the annual audited financial st..., The Company initially filed the annual financi...
(Date:11/6/2009)...stria, November 6 EUCODIS Bioscien...ng, and marketing enzymes for the,chemical industr...rch,agreement with Bio Sidus, the leading biopharm... agreement gives EUCODIS Bioscience exclusive acce...o Sidus, proprietary collection of,psychrophilic b...
Breaking Biology Technology:NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2
...ed for the First Time on 50 mg/Day Dose for PRISTI...ssive Disorder, COLLEGEVILLE, Pa., Dec. 12 Wyeth...), announces that data from,two Phase 3 clinical s...gational serotonin-norepinephrine reuptake inhibit... a 50 mg/day dose of PRISTIQ for the,treatment of ...
...he Netherlands, December 12 , - Forty-five Presti...Response to Customer Demand, Elsevier, a leading ...M) information, today announced that 45 French-lan...e available on ScienceDirect beginning January,3, ...gie, Journal de Chirurgie and,La Press Medicale, r...
...IND has Been Filed With the FDA for the Fourth Gen...Collaboration with Roche., COPENHAGEN, December 1...nvestigational New Drug application (IND) for a,Ge...oration with Roche has,been filed with the FDA by ...velopment of the antibody which selectively blocks...
Other Biology Technology:New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6ScienceDirect to Host French-Language Journals from Elsevier Masson 2ScienceDirect to Host French-Language Journals from Elsevier Masson 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3
(Date:11/4/2009)...t Norman has received more than $10 million in res... the federal stimulus program, bringing thetotal a...rs to $23 million. Thirty-three projects achieved...logy to weather. , "The university has thoughtfu...reasof scholarly excellence to federal agency prio...
(Date:11/4/2009)...PRNewswire-FirstCall/ -- Quest Diagnostics Incorpo...of diagnostic testing, information and services, a...r 30, 2009, income from continuing operations rose... $160 million, or $0.81 per diluted share, for the...ults were reduced by a $0.03 per share charge asso...
(Date:11/4/2009)... Aware, Inc. (Nasdaq: AW...nd biometrics software, today reported financial r...2009. ,, Michael Tzannes, Aware,s Chairman an...e announced an agreement to sell our DSL and home ...semiconductor company being spun out of Infineon. ...
Breaking Biology News(10 mins):OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 1Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 3EGEN Inc Announces the Promotion of Jason Fewell Ph D to Vice President of Preclinical Research and Development 13448 1EGEN Inc Announces the Promotion of Jason Fewell Ph D to Vice President of Preclinical Research and Development 13448 2NeurogesX Reports Second Quarter 2009 Results 13446 1NeurogesX Reports Second Quarter 2009 Results 13446 2NeurogesX Reports Second Quarter 2009 Results 13446 3NeurogesX Reports Second Quarter 2009 Results 13446 4NeurogesX Reports Second Quarter 2009 Results 13446 5NeurogesX Reports Second Quarter 2009 Results 13446 6NeurogesX Reports Second Quarter 2009 Results 13446 7NeurogesX Reports Second Quarter 2009 Results 13446 8NeurogesX Reports Second Quarter 2009 Results 13446 9NeurogesX Reports Second Quarter 2009 Results 13446 10NeurogesX Reports Second Quarter 2009 Results 13446 11NeurogesX Reports Second Quarter 2009 Results 13446 12
...rrow Neurological Institute at St. Joseph,s Hospit...k between eye motions and the perception of illuso...Stephen Macknik, PhD, director of the Laboratory o...e, PhD, director of the Laboratory of Visual Neuro...illan; conducted a study based on the Enigma paint...
... have grown soybeans and turned them into many use...hy a soybean grows, blooms or produces like it doe... , University of Georgia professor Wayne Parrott...million grant from the National Science Foundation...ue. , "I,m convinced that soybeans would be so mu...
... city dwellers posed by Southern California wildfi...restimated by officials. , Detailed particulate a...ia wild fires indicates that the composition posed...generally realized, according to a new paper analy...thern California. , The paper, entitled "Physico...
Other Biology News:Soybean grant gives researchers tools to unravel better bean 2Where there's wildfire smoke, there's toxicity 2
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Nutrient Mixture F-12 Ham, Coon's Modification (Ham's F-12 Coon's) from Sigma-Aldrich
...solution is an isotonic, balanced salt solution. I...ervative, which permits the storage of whole blood... weeks.1 For usage, an equal volume of blood is co...y, but thoroughly, mixed. The solution is placed i...
...Mix or individual RNA sequences from high throughp...om small RNAs from LC Sciences. These products pro...ons) of DESIGNED sequences delivered in a microtub...taining a single verified RNA sequence. This is a ...
Biology Products: